李秋美
林靖麒
林科名
王文科
謝清川
陳肇寅
郭昶甫
曾啟權
江博暉
林宜君
楊昭輝
林坤成
洪裕強
林志哲
莊文郁
莊蕙青
林素珍
張中明
舒竹青
黃幸宜
郭敏玲
王永樑
羅時成
中野敏明
陳芳馨
周百謙
張國軒
黃冠穎
陳品元
韓仕聰
楊皇煜
賴彬卿
羅淑芬
塗昆樺
許瑞旭
賴振宏
李威震
詹昆明
林承弘
林柏宏
黃璟隆
陳力振
林思偕
劉錦棠
林意旋
沈建忠
吳黃平
胡瀞之
吳宗翰
葉光揚
吳詹永嬌
曾文逸
蔡文彬
廖穗綾
蘇冠文
林胤谷
張心寧
黃澤宏
葉沅杰
李志宏
郭和昌
黃聰龍
楊賢鴻
賴信志
林政道
李文益
陳基益
黃毓惠
沈家瑞
方嘉佑
林怡廷
顧正崙
林錫賢
邱健泰
黃景泰
張文震
邱志勇
傅崇安
林俊彥
周開平
吳承宇
吳庭榕
林展宇
楊智偉
李立夫
陳濘宏
Rajendra Prasad Janapatla
陳奇良
王燕玲
魏福全
陳澤卿
鐘文宏
鍾福財
單位: 林口長庚紀念醫院
現職: 腫瘤科副教授級主治醫師
聯絡地址: 桃園市龜山區復興街五號
電話: 03-328-1200 分機:8825
E-mail: wen1902@hotmail.com
研究領域:
- Oncology 腫瘤
- Immunology 免疫學
- Targeted therapy 標靶治療
- Gene signature
I am especially interested in the diagnosis, treatment and experimental therapy in lung cancer, kidney cancer and skin cancer. My primary area of clinical research is joining global trials to develop novel therapeutic agents, including bevacizumab, sorafenib, sunitinib, axitinib, pazopanib, temsirolimus, everolimus, lapatinib, gefitinib, erlotinib and tasisulam to fight against kidney cancer, lung cancer and malignant melanoma. Currently he is actively involved in the consensus consultation and multi-disciplinary care of the kidney cancer patients, including the staging procedures, management and systemic cytokine and targeted therapies in Taiwan. I am also experienced in translational research, studying specific markers to predict the treatment outcome and safety of patients using targeted therapy. Our team have noticed a high incidence of skin toxicity in Taiwan and published the clinicopathological characteristics of the hand foot-skin reaction in kidney cancer patients receiving multi-kinase inhibitors. Besides kidney cancer, we also published the first paper disclosing a high incidence rate of EGFR mutation in Asian patients with lung adenocarcinoma, which was extremely sensitive to EGFR tyrosine kinase inhibitors. Thus far, we have published more than 100 original articles, scientific reviews and abstracts. Now, I am in charge for the safety and quality-of-care for patients undergoing systemic anticancer therapy in Chang Gung Memorial Hospital to offer every patient the best chance of cure and the least toxicity.
工作經歷:
1989-1992 > Resident in Department of Internal Medicine, Chang Gung Memorial Hospital (CGMH), Taipei, Taiwan
1992-1994 > Clinical Fellow in Division of Medical Oncology, Department of Internal Medicine, CGMH
1994-1995 > Clinical Fellow in Division of Hematology, Department of Internal Medicine, CGMH
1995-1997 > Attending Physician in Medical Oncology, CGMH
1997-1999 > Research Fellow in Department of Surgery, Mount Zion Cancer Center, University of California, San Francisco
1999-present > Attending Physician in Medical Oncology, CGMH
2009-present > Associate Professor
學歷:
1982 - 1989 MD, Chung Shan Medical University, Tai-Chung, Taiwan
代表論文:
1.
Kun-Yun Yeh, Hung-Ming Wang, John Wen-Cheng Chang, Jen-Seng Huang, Chien-Hong Lai, Yii-Jenq Lan, Tsung-Han Wu, Pei-Hung Chang, Hang Wang, Chang-Jer Wu, Simon Hsia, and Cheng-Hsu Wang. Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013, 116(1): 41-48.
2.
Chiao-En Wu, Chia-Hsun Hsieh, Cheng-Jen Chang, Jiun-Ting Yeh, Tseng-tong Kuo, Chih-Hsun Yang, Yung-Feng Lo, Kun-Ju Lin, Yung-Chang Lin, John Wen-Cheng Chang*. Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy. J Formos Med Assoc. 2013, Aug 19. DOI: 10.1016/j.jfma.2013.06.018.
3.
John Wen-Cheng Chang, Nien-Chih Wei, Hung-Ju Su, Jie-Len Huang, Tse-Ching Chen, Yi-Cheng Wu, Chih-Teng Yu, Ming-Mo Hou, Chia-Hsun Hsieh, Jia-Juan Hsieh, Chiao-En Wu, Hsin-Yi Cheng, Todd Hsu and Tzu-Hao Wang. Comparison of Genomic Signatures of Non-small Cell Lung Cancer Recurrence between Two Microarray Platforms. Anticancer Research. 2012, 32(4): 1259-1265.
4.
John Wen-Cheng Chang, Sumitra Thongprasert, Elaine Wright, Kenneth Tsang, Heung-Tae Kim, Myung-Ju Ahn, Joo-Hang Kim, Jin Hyoung Kang, Sang-We Kim, Stefan Walzer. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia Pac J Clin Oncol. 2011, 7(suppl 2): 13-21.
5.
Ying-Ying Li, John Wen-Cheng Chang, Ling-Ling Hsieh, Kun-Yun Yeh. Neutralization of interleukin (IL)-10 released by monocytes/macrophages enhances the up-regulatory effect of monocyte/macrophage-derived IL-6 on expressions of IL-6 and MUC1, and migration in HT-29 colon cancer cells. Cell Immunology. 2010, 265(2): 164-171.
所有論文著作一覽表